Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

2024年12月，辉瑞终止了与Sangamo Therapeutics在A型血友病基因疗法giroctocogene fitelparvovec的合作，将该基因治疗的权益退还给了Sangamo。 近日，基因治疗先驱公司蓝鸟更是在连续几年的挣扎后， ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...